pcn poster

Poster

Utilization of Psychiatric Pharmacogenomic Testing by Primary Care Physicians and Advanced Practice Providers: Confidence and Implementation Barriers

Routine implementation of pharmacogenomic testing for mental health and other conditions treated in primary care may require overcoming barriers such as cost to the patient and knowledge ...

10/26/2023

Valbenazine Improves Tardive Dyskinesia With or Without Concomitant Antipsychotic Therapy: A Meta-Analysis of Three Long-Term Valbenazine Trials

Valbenazine is indicated for once-daily treatment of tardive dyskinesia (TD), a movement disorder associated with prolonged antipsychotic exposure. Data from 3 long-term studies (KINECT™-...

10/26/2023

Veterans’ Intensive PCMHI Boot Camp (VIP Boot Camp)

Veterans Intensive Primary Care Mental Health Integration Bootcamp (VIP Bootcamp): An upstream solution to Mental Health(MH) access issues within the VA system

10/26/2023

Viloxazine ER (Qelbree®) Administered with Psychostimulants in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Topline Results of a Phase IV Safety Trial

Results of a phase IV, open-label safety study evaluating viloxazine ER (Qelbree®) administered with psychostimulants in pediatric (6-17 years) ADHD; morning vs. evening administration of...

10/26/2023

Withdrawal Catatonia: A Rare Case of Treatment-Resistant Catatonia Secondary to Quetiapine Withdrawal

Catatonia is a psychomotor syndrome with well-defined clinical characteristics, although the neurological mechanisms involved remain unknown. In this study, we report a case of a patient ...

10/26/2023

Zuranolone Safety and Tolerability in Adults with Postpartum Depression: Analyses from SKYLARK, a 50 mg Placebo-Controlled Study

In the SKYLARK Study, zuranolone 50 mg was generally well tolerated in adults with postpartum depression; treatment-emergent adverse events (TEAEs) led to zuranolone dose reduction and di...

10/26/2023

Understanding the Real-World Prescription Patterns and Impact of Atypical Antipsychotic Augmentation Timing on Healthcare Cost in Adult Major Depressive Disorder in the United States: A Systematic Literature Review

This study examined the utilization pattern of augmentation with atypical antipsychotics after partial or no response to antidepressants in patients with MDD. The antidepressant prescript...

10/26/2023

Unique Features of the Rapid Mood Screener Enable Detection of Bipolar I Disorder in a Primary Care Practice

The Rapid Mood Screener (RMS) is a self-administered screening tool to help differentiate bipolar I disorder from major depressive disorder. Cases were identified from a primary care sett...

10/26/2023

Use Of VMAT2 Inhibitors For Tardive Dyskinesia In Geriatric Populations - A Case Study

This case report discusses the safety and efficacy of VMAT2 inhibitors in treating antipsychotic induced tardive dyskinesia in adults >55 years old. It also highlights the increased ri...

10/26/2023

Using Chess as a Novel Means to Cure Treatment Refractory Catatonia

The subject matter of the poster includes a case report of a patient with treatment refractory catatonia whose condition rapidly improved following a game of chess, one of the patient's k...

10/26/2023

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Poster

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products